Skip to main content

Kiora Pharmaceuticals, Inc. (KPRX)

NASDAQ: KPRX · IEX Real-Time Price · USD
1.45
-0.04 (-3.02%)
At close: Nov 29, 2021 4:00 PM
1.43
-0.02 (-1.04%)
After-hours:Nov 29, 2021 5:50 PM EST
Market Cap18.28M
Revenue (ttm)12,059
Net Income (ttm)-10.43M
Shares Out12.65M
EPS (ttm)-1.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume291,671
Open1.49
Previous Close1.49
Day's Range1.41 - 1.50
52-Week Range1.35 - 8.18
Beta0.80
AnalystsBuy
Price Target11.83 (+718.7%)
Earnings DateNov 15, 2021

About KPRX

EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveit...

IndustryPharmaceuticals
CEOStephen From
Employees14
Stock ExchangeNASDAQ
Ticker SymbolKPRX
Full Company Profile

Financial Performance

In 2020, KPRX's revenue was $12,059, a decrease of -99.55% compared to the previous year's $2.69 million. Losses were -$8.09 million, 14.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for KPRX stock is "Buy." The 12-month stock price forecast is 11.83, which is an increase of 718.69% from the latest price.

Price Target
$11.83
(718.69% upside)
Analyst Consensus: Buy

News

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and...

2 weeks ago - GlobeNewsWire

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy

SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade...

3 weeks ago - GlobeNewsWire

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bay...

EyeGate adds Bayon Therapeutics' portfolio of vision-restoring small molecules to its development pipeline EyeGate adds Bayon Therapeutics' portfolio of vision-restoring small molecules to its developme...

1 month ago - GlobeNewsWire

7 Best Penny Stocks to Buy on the Nasdaq for October

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

2 months ago - InvestorPlace

Best Penny Stocks to Buy Right Now? 3 to Watch in October

Investing in penny stocks in 2021? Check these three out for next months watchlist The post Best Penny Stocks to Buy Right Now?

Other symbols:EXPRKOS
2 months ago - PennyStocks

Penny Stocks For Your Biotech Watch List In September 2021

Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:AMPECASICFMSCLVS
2 months ago - PennyStocks

4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507%

Biotech Penny Stocks Surge As Sector Reverses Course The post 4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507% appeared first on Penny Stocks to Buy, Picks, News and Information | ...

Other symbols:BDSIENVBOPGN
2 months ago - PennyStocks

EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercial...

2 months ago - GlobeNewsWire

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of ...

-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-

2 months ago - GlobeNewsWire

Top Penny Stocks You Need to Know About Right Now

Are these top penny stocks on your small-caps watchlist The post Top Penny Stocks You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:BDSICTXRSENS
3 months ago - PennyStocks

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treatin...

3 months ago - GlobeNewsWire

EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating...

3 months ago - GlobeNewsWire

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating...

3 months ago - GlobeNewsWire

EYEG Stock: 2 Big Things to Know About EyeGate Pharma as Shares Soar 100%+

EYEG stock continues its acquisition plans with its intent to buy Bayon Therapeutics in an all-stock transaction. Here's what to know.

4 months ago - InvestorPlace

Why Eyegate Pharmaceuticals Shares Are Skyrocketing Today

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) shares are trading higher by 116% at $6.74 Tuesday morning after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics f...

4 months ago - Benzinga

Why Shares Of Eyegate Pharmaceuticals Spiked After Hours Monday

Eyegate Pharmaceuticals (NASDAQ: EYEG) shares are trading higher Monday afternoon after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics for roughly $7.1 mil...

4 months ago - Benzinga

EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D.

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- -EyeGate signs non-bi...

4 months ago - GlobeNewsWire

EyeGate Pharma Stock Jumps On Initiation Of Proof Of Concept Trial With DHODH Inhibitor In Ophthalmology Indications

EyeGate Pharmaceuticals Inc (NASDAQ: EYEG) has dosed the patient in Phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocul...

5 months ago - Benzinga

EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study

- Proof-of-concept study conducted in Austria- -Topline data expected in Q4 2021-

5 months ago - GlobeNewsWire

EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21-

6 months ago - GlobeNewsWire

EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and ...

7 months ago - GlobeNewsWire

EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update

WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treati...

8 months ago - GlobeNewsWire

EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation

- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development -

9 months ago - GlobeNewsWire

EyeGate Enters Into Agreement for $8.0 Million Private Placement

WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treatin...

10 months ago - GlobeNewsWire

EYEG Stock: Why EyeGate Pharma Is Up More Than 80% Today

EyeGate Pharma shares doubled on Monday morning following the news of its acquisition of Austria's Panoptes Pharma. Zacks earlier boosted its target on EYEG stock to $15 a share.

11 months ago - InvestorPlace